NO20052379L - Nye antitumorale forbindelser - Google Patents

Nye antitumorale forbindelser

Info

Publication number
NO20052379L
NO20052379L NO20052379A NO20052379A NO20052379L NO 20052379 L NO20052379 L NO 20052379L NO 20052379 A NO20052379 A NO 20052379A NO 20052379 A NO20052379 A NO 20052379A NO 20052379 L NO20052379 L NO 20052379L
Authority
NO
Norway
Prior art keywords
antitumoral compounds
new antitumoral
compounds
antitumoral
new
Prior art date
Application number
NO20052379A
Other languages
English (en)
Other versions
NO20052379D0 (no
NO333448B1 (no
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Pablo Manuel Aviles Marin
Maria Del Carmen Cue Marchante
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of NO20052379D0 publication Critical patent/NO20052379D0/no
Publication of NO20052379L publication Critical patent/NO20052379L/no
Publication of NO333448B1 publication Critical patent/NO333448B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse er rettet mot nye kahalalid-antitumorale forbindelser, i særdeleshet analoger av kahalalid F, som er anvendbare som antitumorale, antivirale, antifungale midler og ved behandling av psoriasis.
NO20052379A 2002-10-18 2005-05-13 Nye 4-metylheksansyre kahalalid F forbindelser, fremgangsmate for deres fremstilling, deres anvendelse for fremstilling av et medikament fortrinnsvis for behandling av kreft, farmasoytiskpreparat omfattende forbindelsene, og et sett som inneholder et farmasoytisk preparat omfattendeforbindelsene. NO333448B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (3)

Publication Number Publication Date
NO20052379D0 NO20052379D0 (no) 2005-05-13
NO20052379L true NO20052379L (no) 2005-07-15
NO333448B1 NO333448B1 (no) 2013-06-10

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052379A NO333448B1 (no) 2002-10-18 2005-05-13 Nye 4-metylheksansyre kahalalid F forbindelser, fremgangsmate for deres fremstilling, deres anvendelse for fremstilling av et medikament fortrinnsvis for behandling av kreft, farmasoytiskpreparat omfattende forbindelsene, og et sett som inneholder et farmasoytisk preparat omfattendeforbindelsene.

Country Status (13)

Country Link
KR (2) KR101149095B1 (no)
AT (1) ATE490975T1 (no)
AU (1) AU2003285911B2 (no)
CA (1) CA2501089C (no)
CY (1) CY1111319T1 (no)
DE (1) DE60335292D1 (no)
DK (1) DK1572726T3 (no)
ES (1) ES2357644T3 (no)
IL (1) IL167724A (no)
NO (1) NO333448B1 (no)
PL (1) PL209129B1 (no)
PT (1) PT1572726E (no)
SI (1) SI1572726T1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
NZ525243A (en) * 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
EP1435990A1 (en) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
KR20050070056A (ko) 2005-07-05
CY1111319T1 (el) 2015-08-05
ES2357644T3 (es) 2011-04-28
DK1572726T3 (da) 2011-03-28
PL377056A1 (pl) 2006-01-23
CA2501089C (en) 2012-07-17
PT1572726E (pt) 2011-02-14
PL209129B1 (pl) 2011-07-29
ATE490975T1 (de) 2010-12-15
KR20110114690A (ko) 2011-10-19
NO20052379D0 (no) 2005-05-13
AU2003285911A1 (en) 2004-05-04
NO333448B1 (no) 2013-06-10
KR101149095B1 (ko) 2012-05-30
IL167724A (en) 2012-01-31
DE60335292D1 (de) 2011-01-20
HK1082261A1 (en) 2006-06-02
CA2501089A1 (en) 2004-04-29
AU2003285911B2 (en) 2009-11-19
SI1572726T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
NL300933I2 (nl) Letermovir
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
NO20082298L (no) Kaliumkanalinhibitorer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20055741D0 (no) Nye kjemiske forbindelser
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
SE0200843D0 (sv) Chemical compounds
DE60329326D1 (de) Tace inhibitoren
WO2004035613A3 (en) 4-methylhexanoic kahalaide f compound
EA200200948A1 (ru) Лечение псориаза
NO20052379L (no) Nye antitumorale forbindelser
EA200401032A1 (ru) Антиинфарктные молекулы
BR0312183A (pt) Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica
NO20055002L (no) Benzol[1,2,5]tiadiazolforbindelser
DE60221420D1 (de) Trennung von regioisomeren von metallphthalocyaninen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees